ABSI vs RXRX
ABSI and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABSIABSCI CORP | RXRXRECURSION PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $1.37B | $1.76B |
| P/S | 487.3x | 23.2x |
| Revenue growth (YoY) | -38.2% | 26.9% |
| Earnings growth (YoY) | -11.7% | -39.1% |
| EBIT margin | -4297.0% | -867.9% |
| ROE | -46.8% | -70.5% |
| ROIC | -84.6% | -175.2% |
| 1y total return | +193.9% | -33.0% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: ABSI vs RXRX
| 지표 | ABSI | RXRX |
|---|---|---|
| 최종 가치 | $3.7K | $914 |
| 총수익률 | -63.0% | -90.9% |
| CAGR | -17.6% | -37.1% |
| 변동성 | 97.7% | 92.7% |
| 샤프 | 0.24 | -0.11 |
| 소르티노 | 0.36 | -0.17 |
| 최대 낙폭 | -96.2% | -92.1% |
공통 거래일 1294일 기준, 2021-07-22 → 2026-09-16 · 무위험수익률 4.11% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)